--- title: "Humacyte (HUMA) news: class action, offering and Nasdaq notice" url: "https://aibio.space/companies/humacyte/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "HUMA class action, offering and Nasdaq notice news: Humacyte securities suit over Symvess safety enters discovery; four derivative suits pending." --- HUMA Humacyte, Inc. NASDAQ · United States # Humacyte (HUMA) news HUMA class action, offering and Nasdaq notice news Legal · 2026-08-12 ## [Humacyte securities suit over Symvess safety enters discovery; four derivative suits pending](https://aibio.space/news/humacyte-securities-suit-symvess-safety-enters-discovery-four/) The North Carolina class action names Humacyte and certain officers. Derivative suits name current or former directors and officers, and Ayabudge LLC in two cases. Product safety claims survived dismissal. ## Latest Humacyte news 1. 2026-05-08 Listings [Humacyte gets Nasdaq minimum bid price deficiency notice, has until November 2, 2026](https://aibio.space/news/humacyte-gets-nasdaq-minimum-bid-price-deficiency-notice-has-until/) Nasdaq told Humacyte on May 4, 2026 that its common stock closed below $1.00 for 30 consecutive business days. The company has until November 2, 2026 to regain compliance, and the notice has no immediate effect on its listing. 2. 2025-10-07 Financings [Humacyte prices $60.0 million registered direct offering of stock and warrants](https://aibio.space/news/humacyte-prices-60-0-million-registered-direct-offering-stock-warrants/) Humacyte is selling 28,436,018 shares, with warrants for the same number of shares, at $2.11 per share and warrant. The release does not say how the proceeds will be used. ## Humacyte at a glance - **Ticker**: HUMA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $79.9 million ### Related companies - [Beam Therapeutics](https://aibio.space/companies/beam-therapeutics/) NASDAQ: BEAM - [SKYTECH ORION GLOBAL CORP.](https://aibio.space/companies/skytech-orion-global/) OTC: SKTG - [ThermoGenesis Holdings](https://aibio.space/companies/thermogenesis/) OTC: THMO - [MBX Biosciences](https://aibio.space/companies/mbx-biosciences/) NASDAQ: MBX - [MetaVia](https://aibio.space/companies/metavia/) NASDAQ: MTVA - [Greenwich LifeSciences](https://aibio.space/companies/greenwich-lifesciences/) NASDAQ: GLSI - [Imunon](https://aibio.space/companies/imunon/) NASDAQ: IMNN - [Kymera Therapeutics](https://aibio.space/companies/kymera-therapeutics/) NASDAQ: KYMR ### Also on NASDAQ - [Kalaris Therapeutics](https://aibio.space/companies/kalaris-therapeutics/) KLRS - [Mustang Bio](https://aibio.space/companies/mustang-bio/) MBIO - [LeonaBio](https://aibio.space/companies/leonabio/) LONA - [iSpecimen](https://aibio.space/companies/ispecimen/) ISPC - [Mangoceuticals](https://aibio.space/companies/mangoceuticals/) MGRX - [Rocket Pharmaceuticals](https://aibio.space/companies/rocket-pharmaceuticals/) RCKT ## What Humacyte does Humacyte is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale. It began the United States commercial launch of its first FDA-approved product, Symvess (acellular tissue engineered vessel-tyod, or ATEV), in the first quarter of 2025. The company believes its regenerative medicine technology has the potential to overcome limitations in existing standards of care. Its strategic partnership with Fresenius Medical Care Holdings covers the sale, marketing and distribution of its 6 millimeter ATEV for certain specified indications and markets, if approved by regulatory authorities. Humacyte is running the Phase 3 V007 and V012 clinical trials and has ongoing discussions with the FDA about the design of its clinical trials. The company also relies on third-party manufacturers, licensors and suppliers, and it says it must manufacture its products in sufficient quantities to satisfy clinical trial and commercial needs. | Product or program | What it is | Stage | |---|---|---| | Symvess (acellular tissue engineered vessel-tyod, ATEV) | Bioengineered tissue vessel for implantation, first FDA-approved product | approved in the US | | 6 millimeter ATEV | Vessel to be sold with Fresenius Medical Care for specified indications and markets | | Summarised from the company's [10-K filed Mar 27, 2026](https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/huma-20251231.htm). ## Humacyte annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$2.0 million](https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/) | [$0](https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/) | | Research and development | [$69.3 million](https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/) | [$88.6 million](https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/) | | Net income (loss) | [-$40.8 million](https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/) | [-$148.7 million](https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/) | | Cash from operations | [-$105.0 million](https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/) | [-$98.1 million](https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/) | | Cash and equivalents | [$50.5 million](https://www.sec.gov/Archives/edgar/data/1818382/000119312526347022/) | [$44.9 million](https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $79.9 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Humacyte Is there a class action against Humacyte? Our latest story on this, dated Aug 12, 2026: "Humacyte securities suit over Symvess safety enters discovery; four derivative suits pending". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/humacyte-securities-suit-symvess-safety-enters-discovery-four/). Has Humacyte raised money recently? Our latest story on this, dated Oct 7, 2025: "Humacyte prices $60.0 million registered direct offering of stock and warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/humacyte-prices-60-0-million-registered-direct-offering-stock-warrants/). Has Humacyte received a Nasdaq deficiency notice? Our latest story on this, dated May 8, 2026: "Humacyte gets Nasdaq minimum bid price deficiency notice, has until November 2, 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/humacyte-gets-nasdaq-minimum-bid-price-deficiency-notice-has-until/). What is the ticker symbol of Humacyte? Humacyte, Inc. trades under the ticker HUMA on NASDAQ. Where is Humacyte listed? Humacyte, Inc. is listed on NASDAQ. What is the SEC CIK of Humacyte? The SEC Central Index Key (CIK) for Humacyte, Inc. is 1818382. Its filings are on SEC EDGAR. How many shares does Humacyte have outstanding? 277,798,105 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Humacyte listed under? Our directory records Humacyte, Inc. under United States. What does Humacyte do? Our directory classifies Humacyte, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Humacyte? The ISIN recorded for Humacyte, Inc. is US44486Q1031. Does aibio.space cover Humacyte? aibio.space lists Humacyte, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Humacyte incorporated? SEC records list its state or country of incorporation as DE. What does Humacyte develop? Humacyte is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale. It began the United States commercial launch of its first FDA-approved product, Symvess (acellular tissue engineered vessel-tyod, or ATEV), in the first quarter of 2025. What is Symvess (acellular tissue engineered vessel-tyod, ATEV) from Humacyte? Symvess (acellular tissue engineered vessel-tyod, ATEV): Bioengineered tissue vessel for implantation, first FDA-approved product Stage: approved in the US. What is 6 millimeter ATEV from Humacyte? 6 millimeter ATEV: Vessel to be sold with Fresenius Medical Care for specified indications and markets ## Investor discussion: Humacyte Members talk about Humacyte (HUMA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Humacyte, newest first. Each line links the filing it comes from. 1. 2026-08-25 Listings Filed to remove its shares from exchange listing. SEC Form 25-NSE. [Source](https://www.sec.gov/Archives/edgar/data/1818382/000135445726000819/xslF25X02/primary_doc.xml) 2. 2026-08-12 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1818382/000119312526347022/huma-20260630.htm) 3. 2026-07-31 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1818382/000110465926089281/tm2621850d1_8k.htm) 4. 2026-06-10 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1818382/000110465926072391/tm2616944-1_424b5.htm) 5. 2026-06-09 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1818382/000110465926071862/tm2617355d1_8k.htm) 6. 2026-06-05 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1818382/000110465926071000/tm2616944d2_8k.htm) 7. 2026-05-08 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1818382/000110465926057974/tm2614071d1_8k.htm) 8. 2026-03-27 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/huma-20251231.htm) 9. 2026-03-19 Financings Reported a financing. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1818382/000110465926032116/tm269106d2_ex99-1.htm) 10. 2025-12-15 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1818382/000110465925120915/tm2533185d2_8k.htm) 11. 2025-12-15 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1818382/000110465925121214/tm2533185d3_8k.htm) 12. 2025-11-26 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1818382/000110465925116476/tm2532300d1_8k.htm) 13. 2025-10-07 Financings Reported a financing. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1818382/000110465925097591/tm2528189d1_ex99-1.htm) 14. 2025-06-11 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1818382/000181838225000080/huma-20250610.htm) 15. 2025-03-26 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1818382/000110465925028270/tm258849-3_424b5.htm) 16. 2024-11-14 Financings Reported a financing. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1818382/000110465924119013/tm2428460d1_ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:HUMA on TradingView](https://www.tradingview.com/symbols/NASDAQ-HUMA/). ## SEC filings and registration - **SEC name**: Humacyte, Inc. - **CIK**: 1818382 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: HUMA (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM, NC, 27713 - **Phone**: 919-313-9633 - **Shares outstanding**: 277,798,105 as of 2026-08-10 (10-Q filed 2026-08-12) - **Former names**: Alpha Healthcare Acquisition Corp. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1818382/000181838226000011/huma-20260922.htm) filed 2026-09-28 - [10-Q](https://www.sec.gov/Archives/edgar/data/1818382/000119312526347022/huma-20260630.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1818382/000110465926094440/tm2622949d1_8k.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1818382/000110465926089281/tm2621850d1_8k.htm) filed 2026-07-31 - [8-K](https://www.sec.gov/Archives/edgar/data/1818382/000110465926072980/tm2617224d2_8k.htm) filed 2026-06-11 - [424B5](https://www.sec.gov/Archives/edgar/data/1818382/000110465926072961/tm2616944-3_424b5.htm) filed 2026-06-11 - [424B5](https://www.sec.gov/Archives/edgar/data/1818382/000110465926072391/tm2616944-1_424b5.htm) filed 2026-06-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1818382/000110465926072382/tm2617224d1_8k.htm) filed 2026-06-10 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001818382), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Humacyte, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker HUMA, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Humacyte, Inc. - **Ticker**: HUMA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US44486Q1031 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-HUMA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/humacyte/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Humacyte (HUMA) news: class action, offering and Nasdaq notice", 2026-10-31, https://aibio.space/companies/humacyte/